AstraZeneca LP (NYSE: AZN) today announced the release of a new, new and expanded range of generic Strattera (atomoxetine). Strattera is a generic version of the popular stimulant medication, atomoxetine HCl. Strattera is the brand name for the drug.
The brand name for atomoxetine, which is used to treat attention deficit hyperactivity disorder (ADHD), was originally released as a generic version of Strattera. The drug was approved for retail sale in the U. S. in September 1999. Since then, atomoxetine has been available as a generic prescription drug and has been available in a combination drug form as atomoxetine HCl.
“Our recent press release highlights that Strattera is a highly effective treatment option for ADHD,” said Dr. David S. Gerber, chief executive officer, AstraZeneca LP. “Our new generic version of atomoxetine has been brought to market in many countries with high demand. Our launch will add the ability to prescribe generic atomoxetine as a first-line treatment for ADHD patients.”
Strattera’s current price is approximately $17 per tablet. The price may vary depending on the dosage and quantity of the tablet, as well as the pharmacy. Generic Strattera can cost as little as $5 per tablet. However, some generic atomoxetine manufacturers may charge for the drug as little as $10 for a 10 mg tablet. Patients taking other stimulants who are prescribed a lower dose may be able to obtain a more affordable alternative.
“We are pleased to introduce the launch of generic Strattera, which has been approved for retail sale in the U. and internationally,” said Dr. Michael L. Lechleiter, director of research and product development, AstraZeneca LP. “Our generic atomoxetine was approved in the U. in April 1999 and has been available for over 15 years. We look forward to continuing our collaboration with Eli Lilly and Company and the launch of our generic version of Strattera.”
“We are proud to be a leading supplier of generic Strattera across our diverse global portfolio,” said Peter Klink, president of AstraZeneca LP. “The availability of generic atomoxetine in the U. is a significant milestone for us. We look forward to the ability to market this drug to patients at all stages of their treatment.”
The U. Food and Drug Administration (FDA) approved Strattera in 1999, and it is currently the first drug approved for ADHD in the United States. The drug is available as a generic alternative in a 10 mg/ml (5 mg/mL) strength. It is also the first of a new class of drugs to be approved for the treatment of ADHD, with the drug being indicated for both ADHD and for the prevention and treatment of other conditions.
Strattera is available in 100 mg, 150 mg, and 300 mg strengths, and the generic form comes in 10 mg, 20 mg, 40 mg, and 80 mg strengths.
For further information, please visit:
About AstraZeneca
AstraZeneca LP is a global specialty pharmaceutical company committed to innovation, quality, and drive growth. As a global leader in pharmaceutical services and products, AstraZeneca LP focuses on providing healthcare solutions to customers around the world. By leveraging the latest research and industry insights, AstraZeneca LP provides healthcare solutions to healthcare professionals across a wide variety of applications, including:
1. Treatment of Attention Deficit Hyperactivity Disorder (ADHD):
2.
A study has shown that adults in the US have a significant risk of dying from heart disease when prescribed a second type of medication, a new study shows.
The research, conducted by the University of Texas Health Science Center at Galveston, shows that heart disease medications were more likely to be prescribed to people who took the second-generation non-stimulant drug, Strattera, than those who were prescribed it.
“The findings were published today in the British Medical Journal,” said study author, Dr. David A. Wiggers, MD, MPH, of the University of Texas Southwestern Medical Center.
“They were taking it on a very individual basis to make sure they were going to get it.”
The study, in part, was prompted by a study by Drs. Elizabeth Kavaler, MD, of the University of Pittsburgh and colleagues published recently in the journalJournal of the American College of Cardiology.
The research, which was conducted by the University of Texas College of Medicine and colleagues, showed that adults in the US had a significant risk of dying from heart disease when prescribed a second type of medication, a second-generation non-stimulant drug called atomoxetine, than those prescribed it with a placebo.
The study was prompted by a study by Drs. Elizabeth Kavaler, MD of the University of Texas Southwestern Medical Center and colleagues, and colleagues published recently in the journal
The study, which was also sponsored by Drs. Elizabeth Kavaler, MD, of the University of Pittsburgh and colleagues, was designed to determine whether it is safe for people to take the second-generation drug, atomoxetine, to treat ADHD, which is often the result of the overuse of stimulant medications, such as Ritalin.
“The main thing is that people taking atomoxetine should be aware of the potential dangers,” Wiggers said.
“There is a lot of confusion about these issues. People shouldn’t be taking atomoxetine, and that’s where the new study comes in.”
The study was conducted by the University of Texas College of Medicine and colleagues and was conducted by the University of Texas Health Science Center at Galveston, with assistance from the Texas Heart Institute and the Texas Heart abscess program.
The researchers found that those taking atomoxetine had a slightly lower risk of death in their study compared to those who were prescribed atomoxetine with a placebo.
Dr. Wiggers said that the findings may not apply to patients in other settings, such as the US, where there is no standard for the amount of medicine that can be given to people.
“In those countries, it may be harder to get some of the medicines that are available for people to get them,” he said.
The new study, which was conducted at the University of Texas Southwestern Medical Center, is expected to be published in the journalJAMA Internal Medicine
Kavaler and colleagues were not involved in the study, but Wiggers and colleagues acknowledge they were interested in conducting the study. He said they have no direct financial or medical ties to the company or its employees.
A spokesperson for the university declined to comment.
“Our goal is to ensure that all American adults have access to the highest quality of life and quality of life that is their highest priority,” said Dr. Kavaler.
“We’re not a one-size-fits-all health care system; we’re all about getting the best possible treatment for our patients.”
In the new study, Wiggers compared atomoxetine with a placebo in adults with ADHD, and found that atomoxetine was more likely to be prescribed to adults than a placebo, the researchers said.
“People who took atomoxetine had a slightly lower risk of death in their study compared to those who were prescribed it with a placebo,” Wiggers said. “However, patients taking atomoxetine in their care should be aware of the potential dangers.
“That said, we’re not a one-size-fits-all health care system; we’re all about getting the best possible treatment for our patients.
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
healthcareylife_pillsdiagnosis
Strattera is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in adults.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Research shows that these non-stimulants are not superior to prescription medications in terms of reducing symptoms of depression, weight loss, treating anxiety or relieving pain. This medicine is also not approved for the treatment of opioid dependence. This medicine is not indicated for the treatment of children under the age of 18 years.
This medicine is a prescription only medicine. Keep all medicine out of the reach of children and pets and use this medicine in the same order as your doctor would prescribe it. Do not give this medicine to anyone under the age of 18 years; it was never prescribed for you.
Do not use this medicine with any other medicine or supplements, even if there are no benefits. - This medicine is a prescription only medicine.
How to treat adderallAtherosclerosis is a disease that is characterized by the accumulation of fats in the blood, resulting in a narrowing of the blood vessels carrying blood into the brain. Symptoms of an atherosclerosis include muscle weakness, ankle/foot pain, swelling, and seizures. Treatment of this disorder is essential to relieve symptoms such as:
If you have an enlarged prostate, then you may have a sudden decline in hearing ability. You may have a hearing loss if you have one. A sudden decrease in hearing is not expected to be noticed in the presence of the symptoms.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy in the United States, as a 10 ml oral suspension (2ml-15ml) in a dosing syringe. This product contains free andCome over from your Doctor. This product is a Prescription Only Medicine (S4).
This product description is a Prescription Only Medicine (S4).
The mixture of metronidazole and propyl alcohol is used for the treatment of alcohol use disorder (AUD) in the US. Metronidazole, in the form of a hydrophilic derivative, has anti-inflammatory, antipsychotic, and vasodilator properties that may help to reduce the risk of seizures.
Common side effects include nausea, headache, and dizziness. In severe cases, it may cause a life-threatening reaction with an extremely high risk of causing a fatal, life-threatening condition. This drug is also used for the treatment of Parkinson's disease (PD).
The drug is also used to treat symptoms of anorexia (adults) and bulimia (children ages 6 to 17).
A combination of metronidazole and propyl alcohol is used to treat alcoholism. This alcohol-alcohol association is not well established.
This drug is also used to treat symptoms of PD.
This drug is also used to treat symptoms of anorexia (adults) and bulimia (children ages 6 to 17).
The mixture of metronidazole and propyl alcohol is used to treat symptoms of anorexia (adults) and bulimia (children ages 6 to 17).
CNS is a relatively new drug class.
The store will not work correctly in the case when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Strattera-100-MG-Oral-Tablet
Atom: 513
Telmisartan + 513 is a combination of two medicines used to treat heart disease, which is a condition that causes chest pain and shortness of breath. If you are experiencing symptoms of heart disease or allergic reactions (such as trouble breathing or swallowing, swelling of the throat, or tightness or rupture of the throat), you need to see your doctor. The first step is to see that your doctor approves it. The second step is to take it as prescribed and to speak to your doctor. It can take up to 4 weeks for it to be effective, so if you stop taking it, it can cause withdrawal symptoms. If you have any questions, please talk to your doctor.
Stade de France Pharmacy